---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-024726"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:51:25.050320+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OS Therapies raises $2M via 10% OID convertible notes and warrants; $2.2M principal

## Summary
- Gross proceeds $2M; notes carry 4% interest, mature March 4, 2027.
- Warrants to purchase up to 1,666,667 shares at $1.40, 5-year term; 100% warrant coverage.
- Conversion: mandatory upon qualified offering ≥$2.5M; voluntary at 90% of 10-day VWAP.
- Proceeds to fund clinical trials, R&D, and working capital.
- 19.99% issuance cap without stockholder approval; resale registration to be filed within 30 days.

## SEC filing metadata
- accession: 0001213900-26-024726
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390026024726/0001213900-26-024726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390026024726/ea0280014-8k_ostherapies.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-024726
- JSON: https://secwatch.observer/filing/0001213900-26-024726.json
- Plain text: https://secwatch.observer/filing/0001213900-26-024726.txt

## Source-grounded claims
- claim_id: 707b0b469e1a4e2811dc7e7647bdb5d2c08e1646
  claim: OS Therapies Inc incurred convertible notes of $2,200,000 at 4% per annum maturing March 4, 2027.
  evidence_excerpt: Pursuant to the Purchase Agreement, the Company issued to the Purchasers (i) Notes in an aggregate principal amount of $2,200,000 and (ii) Warrants to purchase up to 1,666,667 shares of the Company’s common stock (the “Warrant Shares”), for aggregate gross proceeds of $2,000,000, before deducting placement agent fees and other Private Placement expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1795091/000121390026024726/0001213900-26-024726-index.htm
- claim_id: 3325e6b6801fbea9cdca8c9e6a2d8ffa935c7e06
  claim: OS Therapies Inc entered into Purchase Agreement with certain accredited investors valued at $2,200,000 aggregate principal amount of Notes and $2,000,000 aggregate gross proceeds (effective 2026-03-04).
  evidence_excerpt: On March 4, 2026, OS Therapies Incorporated (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors (collectively, the "Purchasers"), pursuant to which the Company agreed to issue and sell to the Purchasers, in a private placement (the "Private Placement"), (i) 10.0% original issue discount unsecured convertible promissory notes (the "Notes") and (ii) warrants to purchase shares of the Company's common stock (the "Warrants" and, together with the Notes, the "Securities").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1795091/000121390026024726/0001213900-26-024726-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.